COMPOSITION
Each vial contains:
Cefotaxime Sodium USP
Cefotaxime 1g
CLINICAL PHARMACOLOGY
Pharmacodynamic properties
Pharmacotherapeutic group: Beta-lactam antibiotics, cephalosporins.
ATC Code: J01D D01
Mode of action
Cefotaxime exerts its action by binding to one or more of the penicillin-binding proteins (PBPs)
which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell
walls, thereby inhibiting cell wall synthesis.
Mechanisms of resistance
Resistance to Cefotaxime may be due to one or several of the following mechanisms:
• production of extended-spectrum beta-lactamases (ESBLs)
• induction and/or constitutive expression of AmpC beta- lactamases
• reduced outer membrane permeability
• efflux pump mechanisms.
• Modification of target enzymes (altered PBPs)
More than one of these mechanisms may co-exist in a single bacterium.
PK/PD relationship
Efficacy mainly depends on time above the minimal inhibitory concentration of cefotaxime for
the pathogen(s) to be treated (T/MIC).
Cefotaxime for Injection USP 1g